Biocatalysis in petrochemistry

01Overview and value chain

Markers: [EC: EU Chemicals Strategy for Sustainability & US EPA Green Chemistry | OECD: industrial-biotech | Regulator: EPA (US), REACH (EU), MOA (CN)]

Biocatalysis in petrochemistry deploys engineered enzymes, whole-cell catalysts and cell-free systems to take over synthesis steps that classical petrochemistry still runs over metal and acid catalysts at high temperature and pressure. The enzymatic routes run under mild, near-ambient conditions yet deliver enantioselectivities above 99% ee for chiral building blocks, and immobilized lipases such as CalB hold yields above 95% across many reuse cycles without heavy metals. The addressable industrial-enzyme market spans roughly €20 billion in applications, with the leading biosolutions supplier holding about 48% of the industrial-enzyme share. Where cell-free synthesis is used, protein yields reach up to 3.7 g/L at roughly $39 per gram — a 95% cut in reagent cost — letting biology step directly into continuous petrochemical operation rather than staying at the test-tube scale.

The key directions of biocatalysis in petrochemistry are:

1. Engineered biocatalysts for platform & fine chemicals (Engineered Biocatalysts): machine-learning-driven enzyme engineering (CodeEvolver, roughly one-week design-build-test cycles, an 850+ patent estate) produces chiral amines, alcohols and APIs that replace multi-step thermochemical routes; the portfolio already backs 13 licensed branded pharmaceutical products.
2. Chemoenzymatic cascades for petrochemical building blocks (Chemoenzymatic Cascades): one-pot combinations of chemocatalysis and enzymes valorize biomass and fossil-derived intermediates into aromatics (trans-cinnamic and p-coumaric acid via engineered PAL/TAL) and into high-energy-density polycyclopropanated fatty acids (POP-FAs) for aviation biofuels.
3. Immobilized & cell-free biocatalysis at scale (Immobilized & Cell-Free): reusable immobilized CalB reactors operate at multi-tonne scale for active pharmaceutical ingredients, while cell-free systems reach 3.7 g/L at about $39/g, moving enzymatic catalysis into continuous flow.
4. De novo enzyme design for new-to-nature reactions (De Novo Design): catalytic-motif scaffolding plus diffusion models (TRL 4) create enzymes for reactions no natural enzyme performs — 99% ee and stable above 90°C — unlocking petrochemical targets outside biology’s existing repertoire.

Sectoral value chain

[Biocatalyst R&D] ──> [Fermentation] ──> [Immobilization] ──> [Biocatalytic conversion]
                              │
                    (submerged or cell-free)
                              │
                              ▼
[Drop-in chemical] <─── [Cascade + recovery] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• ML enzyme engineering (CodeEvolver / Directed Evolution): machine-learning plus bioinformatics plus automated lab compress design-build-test to about one week, trained on 20+ years of experimental data.
• Immobilized & cell-free biocatalysis (Immobilized CalB / Cell-Free): reusable immobilized lipases and cell-free lysates move enzymatic catalysis into continuous, heavy-metal-free operation.
• De novo computational enzyme design (De Novo Design): catalytic-motif scaffolding with diffusion and atomistic refinement produces active enzymes for reactions outside nature’s repertoire.

02US

The United States anchors the enzyme-engineering and biofuel-biocatalysis stack, with EPA green-chemistry policy and a deep pharma-biocatalysis customer base pulling engineered enzymes into both drug and chemical manufacturing.

enzyme-engineering platforms, pharma & biofuel biocatalysis, drop-in biochemicals

• Codexis (Redwood City): the CodeEvolver platform licenses custom enzyme engineering to Merck and partners; an 850+ patent estate and ECO Synthesis manufacturing platform back 13 licensed branded pharmaceutical products, with $65.1M cash on hand at Q1 2026.
• Ginkgo Bioworks (Boston): enzyme and strain engineering for aromatics (engineered PAL/TAL to trans-cinnamic and p-coumaric acid), oxygenated hydrocarbons and polycyclopropanated fatty acids (POP-FAs) for aviation biofuels.
• EPA Green Chemistry & TSCA framework: regulatory pull for enzymatic routes that cut hazardous reagent use under the Sustainable Chemistry Research and Development Act and TSCA new-chemical review.

03CN

China couples its position as the largest petrochemical manufacturer with a fast-growing industrial-enzyme base, integrating biocatalytic and bio-based steps into mega-refinery complexes to diversify away from imported oil and meet carbon-peak targets.

industrial-enzyme champions, mega-refinery integration, R&D-intensive biomanufacturing

• Vland Biotech (蔚蓝生物, 603739): China’s listed industrial-enzyme champion; 2025 revenue of ¥13.66 billion (+3.43%) with enzyme gross margin of 65.12% and R&D at 10.19% of revenue, and 2026Q1 net profit up 86.57%.
• Sinopec: integration of bio-based and biocatalytic steps into state-owned mega-refinery and olefins complexes, building domestic drop-in biochemical capacity at industrial scale.
• National biomanufacturing push: state directives route green-manufacturing and bioeconomy funding into enzyme and cell-factory platforms that feed petrochemical value chains.

04EU

The European Union sets the most demanding chemicals-regulation environment (REACH, Chemicals Strategy for Sustainability), which simultaneously forces substitution of hazardous catalysts and creates a premium market for biosolutions and immobilized biocatalysis.

biosolutions leadership, immobilized biocatalysis scale-up, de novo enzyme design

• Novonesis (Copenhagen): the post-merger biosolutions leader holds about 48% of the industrial-enzyme share against a €20 billion addressable market; 2026 EBITDA guided at €1.668B, with a SEQENS partnership delivering industrial biocatalytic processes for fine chemicals and the €1.5B Feed Enzyme Alliance acquisition deepening integration.
• EnginZyme (Stockholm): immobilized CalB flow reactors, partnered with Almac, run Candida antarctica lipase B at multi-kilogram to tonne scale for API and intermediate synthesis under mild, reusable conditions.
• Enzymicals (Greifswald) & acib (Graz): biocatalytic process scale-up (imine reductase for multi-tonne tobacco-free (S)-nicotine; CAL-B lipases above 95% yield for clean-beauty esters) and TRL-4 de novo enzyme design by catalytic-motif scaffolding reaching 99% ee.

05Leading companies and research institutes

06Tech stack and innovations

The petrochemical biocatalysis stack is built on protein engineering, computational design and continuous-flow biocatalysis, with machine learning now compressing the path from a new reaction to a manufacturable catalyst.

1. ML-driven enzyme engineering (CodeEvolver / Directed Evolution):
   • Machine learning plus bioinformatics plus automated lab deliver roughly one-week design-build-test cycles, trained on 20+ years of proprietary data rather than public datasets alone.
   • An 850+ patent estate (with 2026 transaminase patents for chiral compounds) underpins a portfolio supporting 13 licensed branded pharmaceutical products and the ECO Synthesis enzymatic RNA/siRNA platform.
2. Immobilized & cell-free biocatalysis (Immobilized CalB / Cell-Free):
   • Immobilized CalB (Candida antarctica lipase B), partnered with Almac, runs esterification and transesterification at multi-kilogram to tonne scale, reusable across cycles under mild, heavy-metal-free conditions at yields above 95%.
   • Cell-free protein synthesis reaches up to 3.7 g/L at about $39/g — a 95% reagent-cost reduction — and machine-learning-guided spatial enzyme assembly lifts cell-free flavonoid titers to 439.42 mg/L.
3. De novo computational enzyme design (De Novo Design):
   • Catalytic-motif scaffolding with a hybrid diffusion/atomistic pipeline (Riff-Diff, LigandMPNN, FastRelax, ESM/AlphaFold), at TRL 4 with acib and Graz University of Technology, yields active, enantioselective enzymes (99% ee) stable above 90°C from only a few dozen sequences.
   • ProteinMPNN-based sequence redesign of glycosyltransferases lifted fed-batch titers to 2.11 g/L cichoriin and 4.05 g/L aesculin, a generalizable route for difficult-to-express enzymes in microbial cell factories.

07Value chains and production pipelines

Industrial pipeline of biocatalytic petrochemical synthesis (ISO 9001 / REACH)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Biocatalyst engineering│ ───> │ 2. Fermentation & lysate  │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Biocatalytic conversion│ <─── │ 3. Immobilization / CF    │
└───────────────────────────┘      └───────────────────────────┘
               │
               ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Chemoenzymatic cascade │ ───> │ 6. Recovery & reuse       │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Biocatalyst engineering

A target petrochemical transformation is matched to an enzyme family, then optimized by directed evolution and machine-learning platforms (CodeEvolver) in roughly one-week design-build-test cycles, yielding variants with the required activity, selectivity and solvent stability.

Stage 2: Fermentation & lysate

Production strains (engineered microbes) express the enzyme in fed-batch fermentation, or cell-free lysates are prepared directly, supplying crude enzyme or lysate as the catalyst source for the conversion step.

Stage 3: Immobilization / cell-free formulation

The enzyme is bound to a resin, membrane or support for repeated batch or continuous-flow operation (immobilized CalB), or supplied as a formulated cell-free system, producing a reusable catalyst stable across many cycles.

Stage 4: Biocatalytic conversion

The petrochemical substrate is transformed under mild, selective conditions — ketones to chiral amines via transaminases, esters via immobilized CalB at yields above 95%, or aromatics via engineered PAL/TAL — routinely reaching enantioselectivities above 99% ee.

Stage 5: Chemoenzymatic cascade

Compatible chemocatalyst and multi-enzyme steps are telescoped into one pot, so biomass-derived or fossil-derived intermediates flow through several transformations without isolation, cutting separation load and waste.

Stage 6: Recovery & reuse

The product is purified to drop-in chemical grade (polymer or fuel specification) under REACH/ISCC mass-balance accounting, while the immobilized enzyme or cell-free catalyst is recovered and recycled into the next batch.